Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia

Clinical Neuropharmacology

Volumn 35, Issue 6, 2012, Pages 278-282

  Rystedt, Alma ^a   Nyholm, Dag ^a   Naver, Hans ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Nykoping Hospital   (Sweden)

Author keywords

Botox; botulinum toxin; cervical dystonia; dose conversion ratio; Dysport

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CERVICAL DYSTONIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIZZINESS; DOSE CALCULATION; DRUG EFFICACY; DYSPHAGIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREMOR;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; DEGLUTITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TORTICOLLIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870054718     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182711fc0     Document Type: Article

References (17)

1. Wohlfarth K, Goschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997;355(3):335-340. (Pubitemid 27117590)
2. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87(11):719. (Pubitemid 24334671)
3. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994;344(8920):474-475.
4. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003;29(1):7-13; discussion 13. (Pubitemid 36118846)
5. Pickett A, O'Keeffe R, Panjwani N. The protein load of therapeutic botulinum toxins. Eur J Neurol 2007;14(4):e11. (Pubitemid 46481164)
6. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72(4):459-462.
7. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64(1):6-12. (Pubitemid 28156530)
8. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type AVDysport and BotoxVassuming a ratio of 4:1. Mov Disord 1997;12(6):1013-1018. (Pubitemid 27496782)
9. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997;235(4):197-199. (Pubitemid 27326086)
10. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 1995;2:17-18.
11. Marion MH, Sheehy M, Sangla S, et al. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59:102-103.
12. Whurr R, Brookes G, Barnes C. Comparison of dosage effects between the American and British botulinum toxin A product in the treatment of spasmodic dysphonia. Mov Disord 1995;10(3):387.
13. Rystedt A, Swartling C, Naver H. Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations. Acta Dermatovenereol 2008;88(3):229-233. (Pubitemid 351743864)
14. Werdelin L, Dalager T, Fuglsang-Frederiksen A, et al. The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study. Clin Neurophysiol 2011;122(11):2305- 2309.
15. Mohammadi B, Buhr N, Bigalke H, et al. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009;31(5):463-466.
16. Chapman MA, Barron R, Tanis DC, et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007;29(7):1325-1337. (Pubitemid 47348118)
17. Rollnik JD, Matzke M, Wohlfarth K, et al. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol 2000;43(1):9-12. (Pubitemid 30045316)